Emerging experimental drugs in clinical trials for migraine: observations and key talking points
- 3 August 2023
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 32 (8) , 761-771
Abstract
IntroductionThere have been significant advances in the treatment of migraine. In response to the clinical success of monoclonal antibodies targeting calcitonin gene-related peptide, there is interest in the clinical trial outcomes of alternative emerging drugs that act on novel targets associated with migraine pathophysiology. As approximately 50% of patients do not respond to CGRP therapies, there is significant value in future drug innovation. Emerging drugs in clinical trials for the treatment of migraine aim to fill this need.Areas coveredThe emerging drugs that will be discussed in this review include zavegepant, lasmiditan, delta opioid receptor agonists, neuronal nitric oxide synthase inhibitors, monoclonal antibodies targeting pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor, dual orexin receptor antagonists, metabotropic glutamate receptor 5 antagonists, and inducers of ketosis.Expert opinionWhen considering the preclinical and clinical research related to the emerging drug classes discussed in this review, most therapies are derived from highly supported targets of migraine pathogenesis. Although the individual drugs discussed in this review may be of dubious clinical value, the importance of the therapeutic targets on which they act cannot be understated. Future research is necessary to appropriately target the pathways elucidated by preclinical studies.Keywords
This publication has 110 references indexed in Scilit:
- Clinical Predictors for Migraine in Patients Presenting With Nausea and/or VomitingJournal of Neurogastroenterology and Motility, 2013
- Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patientsCephalalgia, 2013
- Opioids Should Not Be Used in MigraineHeadache: The Journal of Head and Face Pain, 2012
- Group I Metabotropic Glutamate Receptor-Mediated Gene Transcription and Implications for Synaptic Plasticity and DiseasesFrontiers in Pharmacology, 2012
- The delta opioid receptor: an evolving target for the treatment of brain disordersTrends in Pharmacological Sciences, 2011
- cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP ActionPharmacological Reviews, 2010
- Glutamate receptor phosphorylation and trafficking in pain plasticity in spinal cord dorsal hornEuropean Journal of Neuroscience, 2010
- Involvement of Corticotrophin-Releasing Factor and Orexin-A in Chronic Migraine and Medication-Overuse Headache: Findings From Cerebrospinal FluidCephalalgia, 2008
- Nitric oxide regulation of calcitonin gene‐related peptide gene expression in rat trigeminal ganglia neuronsEuropean Journal of Neuroscience, 2006
- Identification and Pharmacological Characterization of Domains Involved in Binding of CGRP Receptor Antagonists to the Calcitonin-like ReceptorBiochemistry, 2006